Introduction
W hen compared to conventional nuclear imaging of tumor using radiolabeled antitumor antibodies, pretargeting, in which the radiolabel is administered on a small effector subsequent to the administration of the antitumor antibody, can improve tumor to normal tissue ratios [1] [2] [3] [4] [5] , but only if the effector itself does not accumulate in normal organs. We are interested in applying a novel pretargeting approach using complementary phosphorodiamidate morpholino oliogmers (i.e., MORF/cMORF) to image diseases of the pancreas. Thus far, conventional nuclear imaging of pancreatic cancer with radiolabeled antibodies has met with limited success due to poor pancreas/normal tissue ratios resulting from the accumulation of the radiolabeled antibodies in liver, spleen, intestines, kidneys, and other organs of the abdomen [6, 7] . A potential improvement may be possible by applying pretargeting to the imaging of this organ both for the early detection of cancer and for the imaging of normal pancreatic function in connection with non-cancerous diseases such as diabetes. However, when radiolabeled with technetium-99m ( 99m Tc) and administered to tumored and normal mice, the cMORF effector developed in this laboratory accumulates in the kidneys and intestines. Since numerous reports confirm that radiolabeling with different radionuclides via different chelators can alter the pharmacokinetics of even large molecules such as antibodies [8] [9] [10] [11] , another imaging radionuclide, 111 In, was considered in this study as an alternative to 99m Tc. We now report on the reduced abdominal background level when the cMORF effector is labeled with 111 In in place of 99m Tc.
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Material and Methods
As before, the base sequences of MORF and its complement (cMORF) were, respectively, 5′-TCTTCTACTTCACAACTA-linker-amine and 5′-TAGTTGTGAAGTAGAAGA-linker-amine (GeneTools, Philomath, OR). The DTPA was from Sigma (St Louis, MO) and the EDC (1-Ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride) was from Pierce Company (Rockford, IL). The P-4 resin (Bio-Gel P-4 gel, medium) was purchased from Bio-Rad Laboratories (Hercules, CA InCl 3 solution were both from Perkin Elmer Life Science Inc (Boston, MA). All other chemicals were reagent grade and used without purification.
The antiTAG-72 antibody CC49 was prepared for this investigation by Strategic Biosolutions (Ramona, CA) from the CC49 murine hybridoma cell line (a gift from Dr Schlom, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH). Conjugation of MORF to the CC49 antibody was as reported previously in connection with other antibodies [12] . The Hydralink linker for the conjugation was from Solulink Biosciences (San Diego, CA).
Both the preparation of MAG 3 -cMORF and its use in the labeling with 99m Tc were as previously described [13] .
Preparation of DTPA-cMORF and Radiolabeling with In before purification, the number of DTPA groups per cMORF (gpm) was calculated from the DTPA/cMORF molar ratio in the conjugation mixture and the fraction of radioactivity on the cMORF peak to be 0.17. For radiolabeling, at least 20 μL of the DTPA-cMORF stock solution was mixed with 1-5 μL In-cMORF (5 μg, 1.25 mCi) and were imaged over time on a NanoSPECT small animal camera with CT registration (Bioscan, Washington DC). Each of the acquisitions included 20 projections at 10 s per projection and required about 6-10 min. The total imaging time was a little more than 1 h for each animal.
In groups of five, normal CD-1 mice received either 99m TccMORF (1 μg, 80 μCi) or 111 In-cMORF (1 μg, 10 μCi) and were killed under anesthesia at 15 min. Samples of blood and organs were removed, weighted, and counted in a NaI(Tl) well counter (Cobra II automatic gamma counter, Packard Instrument Company, CT) along with a standard of the injectate. Blood and muscle were assumed to constitute 7% and 40% of body weight, respectively. The whole bladder including contents and the connected urethra and penis were excised and measured in a dose calibrator to estimate urine radioactivity.
Two NIH Swiss nude mice (Taconic Farms, Germantown, NY) were each implanted with LS174T tumor cells in the left thigh. At 13 days, when the tumors were 0. In (400 μCi). The dosages and timing were based on our previous experiences [14] . The 99m Tc mouse was imaged at 3 and 10 h and the
111
In mouse was imaged at 3 and 15 h. The mice were then killed by exsanguination via heart puncture under halothane anesthesia. In addition to normal organs and tissues, the tumored thigh was excised and the skin and as much of the muscle and bone as possible were removed before counting. The radioactivity therein was attributed to the tumor since the radioactivity levels in bone and muscle were negligible. After the tumor thigh was counted, the tumor mass was dissected to isolate the residual bone and muscle so that their weights could be subtracted to provide the net tumor weight.
Results

Biodistributions of Labeled cMORFs in Normal Mice
The labeling procedures for both In-cMORF are shown in Fig. 1 at two time points. Radioactivity in the bladder of both animals has been digitally removed by manually selecting the volume of interest. In the same manner, 111 In urine contamination of the animal's coat was removed from the 68-min image. Whereas both radiolabels accumulated in the kidneys, 99m Tc also accumulated predominately in the hepatobiliary tree, including the gall bladder and small intestines. As expected for hepatobiliary accumulation, the 99m Tc distribution moved over time. The biodistribution results in normal mice via necropsy are shown in Table 1 In, about 60% of the administered radioactivity was in the bladder at 15 min.
Pharmacokinetics of Labeled cMORFs in Pretargeted Mice
The distribution of radioactivity in two tumored nude mice pretargeted with MORF-CC49 antibody is shown in Fig. 2 as posterior and right lateral projections of the acquisitions at 3 and 10 h for The radioactivity accumulations in tumor and kidneys in these two pretargeted mice have been estimated using IVS InvivoScope 1.35 beta1 software (Bioscan). The average results of five independent observers are presented in Table 2 along with that obtained by necropsy. While the accumulations of 99m Tc measured by image quantitation are in agreement with those by necropsy within 10%, this difference is about 40% in the case of 111 In.
Discussion
Although MORF/cMORF pretargeting has been used successfully for nuclear imaging of tumors in mice, the higher accumulations of radioactivity in the intestines following 99m Tc-cMORF administration shown in Figs. 1 and 2 may become problematic when imaging within the abdomen. As shown in Table 1 , about 2% of the administered 99m Tc accumulates in the intestines in the first 15 min following i. v. administration. Furthermore, if the accumulation is in the intestinal contents, as in this case, imaging may be still more problematic by the motion of the contents over time. Fortunately, as shown by both imaging and necropsy, intestinal accumulation was about threefold lower in mice receiving the effector radiolabeled with 111 In. As is evident in Fig. 2 , the accumulations in lung, liver, and kidneys are higher in the pretargeted animals receiving 111 In-cMORF compared to 99m Tc-cMORF. These higher accumulations were not seen in the mice that did not receive In is seen only in the 3-h projections, the liver accumulations appear in both early and late projections. These higher liver accumulations may be due to the residualizing properties of 111 In compared to 99m Tc [15, 16] . In conclusion, the biodistribution of a cMORF effector in both normal and pretargeted tumored mice was influenced by its radiolabel. Tc.
